Clinical Trial

A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to learn more about the study drug GS-1206, including its safety, tolerability, and antitumor activity in adult participants with solid tumors.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-11
notable Trial sites expanded: 0 -> 3 locations 2026-08-11
Trial Details
NCT Number NCT07703878
Lead Sponsor Gilead Sciences
Conditions Solid Tumor
Enrollment 302 participants
Start Date 2026-07-17
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-10